Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency: Rationale and design of CONFIRM-HF study

[1]  P. Ponikowski,et al.  The additive burden of iron deficiency in the cardiorenal–anaemia axis: scope of a problem and its consequences , 2014, European journal of heart failure.

[2]  Luigi Tavazzi,et al.  Co‐morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey , 2014, European journal of heart failure.

[3]  S. Solomon,et al.  Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved , 2014, European journal of heart failure.

[4]  P. Ponikowski,et al.  Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial , 2013, European journal of heart failure.

[5]  J. Verdú,et al.  Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status , 2013, European journal of heart failure.

[6]  P. Ponikowski,et al.  Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK , 2012, European journal of heart failure.

[7]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[8]  P. Ponikowski,et al.  Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches , 2011, Nature Reviews Cardiology.

[9]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.